Jeffrey William Henderson Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now directly owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $57.96 on Tuesday. The business’s 50-day moving average is $54.53 and its two-hundred day moving average is $54.72. The company has a market capitalization of $7.14 billion, a P/E ratio of 16.90, a P/E/G ratio of 0.42 and a beta of 1.25. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its stake in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after purchasing an additional 200 shares in the last quarter. Baird Financial Group Inc. lifted its stake in Halozyme Therapeutics by 2.0% in the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company’s stock worth $532,000 after purchasing an additional 221 shares in the last quarter. Verdence Capital Advisors LLC lifted its stake in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after purchasing an additional 252 shares in the last quarter. Finally, CreativeOne Wealth LLC lifted its stake in Halozyme Therapeutics by 1.6% in the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 294 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. Benchmark reissued a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Piper Sandler upped their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.